UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement

Clinical cancer research, 2018-07, Vol.24 (14), p.3282-3291

2018

Volltextzugriff (PDF)

Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology

Blood, 2012-01, Vol.119 (2), p.411-421

2012

Volltextzugriff (PDF)

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition

Proceedings of the National Academy of Sciences - PNAS, 2016-10, Vol.113 (43), p.12238-12243

2016

Volltextzugriff (PDF)

Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility

The Journal of immunology (1950), 2010-07, Vol.185 (1), p.642-652

2010

Volltextzugriff (PDF)

Integrated mutational landscape analysis of uterine leiomyosarcomas

Proceedings of the National Academy of Sciences - PNAS, 2021-04, Vol.118 (15), p.e2025182118

2021

Volltextzugriff (PDF)

Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2

Blood, 2010-11, Vol.116 (18), p.3677-3680

2010

Volltextzugriff (PDF)

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

Proceedings of the National Academy of Sciences - PNAS, 2019-11, Vol.116 (45), p.22730-22736

2019

Volltextzugriff (PDF)

Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance

Oncogene, 2021-04, Vol.40 (14), p.2509-2523

2021

Volltextzugriff (PDF)

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression

Clinical cancer research, 2017-10, Vol.23 (19), p.5836-5845

2017

Volltextzugriff (PDF)

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells

Molecular cancer therapeutics, 2017-02, Vol.16 (2), p.323-333

2017

Volltextzugriff (PDF)

In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers

Molecular cancer therapeutics, 2018-05, Vol.17 (5), p.1003-1011

2018

Volltextzugriff (PDF)

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors

Proceedings of the National Academy of Sciences - PNAS, 2019-01, Vol.116 (2), p.619-624

2019

Volltextzugriff (PDF)

NOTCH3 expression is linked to breast cancer seeding and distant metastasis

Breast cancer research : BCR, 2018-09, Vol.20 (1), p.105-105, Article 105

2018

Volltextzugriff (PDF)

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

Scientific reports, 2020-01, Vol.10 (1), p.973, Article 973

2020

Volltextzugriff (PDF)

CINNAMON-GUI: Revolutionizing Pap Smear Analysis with CNN-Based Digital Pathology Image Classification [version 1; peer review: awaiting peer review]

F1000 research, 2024, Vol.13, p.897

Zammataro, Luca

2024

Volltextzugriff (PDF)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo

British journal of cancer, 2016-07, Vol.115 (3), p.303-311

2016

Volltextzugriff (PDF)

Pbx1 restrains myeloid maturation while preserving lymphoid potential in hematopoietic progenitors

Journal of cell science, 2013-07, Vol.126 (Pt 14), p.3181-3191

2013

Volltextzugriff (PDF)

Protein domain-based approaches for the identification and prioritization of therapeutically actionable cancer variants

Biochimica et biophysica acta. Reviews on cancer, 2021-12, Vol.1876 (2), p.188614-188614, Article 188614

2021

Volltextzugriff (PDF)

Novel potential oncogenic and druggable mutations of FGFRs recur in the kinase domain across cancer types

Biochimica et biophysica acta. Molecular basis of disease, 2022-02, Vol.1868 (2), p.166313-166313, Article 166313

2022

Volltextzugriff (PDF)

Inactive VEGFR2(R1032Q) exerts pro‐oncogenic activity through heterodimerization with wild‐type receptor

The FASEB journal, 2021-05, Vol.35 (S1), p.n/a, Article fasebj.2021.35.S1.01675

2021

Volltextzugriff (PDF)

Embryonic cleavage modeling as a computational approach to sphere packing problem

Journal of theoretical biology, 2007-03, Vol.245 (1), p.77-82

2007

Volltextzugriff (PDF)

Editorial Expression of Concern: Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function

Nature (London), 2024-03, Vol.627 (8002), p.E7-E7

2024

Volltextzugriff (PDF)

Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence

Cancer letters, 2021-06, Vol.507, p.80-88

2021

Volltextzugriff (PDF)

A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis

Cancer letters, 2021-01, Vol.496, p.84-92

2021

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(51)

Publikationsform

Sprache

Englisch
(54)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement

Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition

Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility

Integrated mutational landscape analysis of uterine leiomyosarcomas

Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells

In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors

NOTCH3 expression is linked to breast cancer seeding and distant metastasis

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

CINNAMON-GUI: Revolutionizing Pap Smear Analysis with CNN-Based Digital Pathology Image Classification [version 1; peer review: awaiting peer review]

Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo

Pbx1 restrains myeloid maturation while preserving lymphoid potential in hematopoietic progenitors

Protein domain-based approaches for the identification and prioritization of therapeutically actionable cancer variants

Novel potential oncogenic and druggable mutations of FGFRs recur in the kinase domain across cancer types

Inactive VEGFR2(R1032Q) exerts pro‐oncogenic activity through heterodimerization with wild‐type receptor

Embryonic cleavage modeling as a computational approach to sphere packing problem

Editorial Expression of Concern: Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function

Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence

A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis

Aktive Filter

Suchergebnisse filtern